thalidomide has been researched along with Pneumonia in 17 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Pneumonia: Infection of the lung often accompanied by inflammation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of lenalidomide, bortezomib and dexamethasone (RVD) has shown excellent efficacy in patients with relapsed or refractory multiple myeloma (RRMM)." | 7.79 | Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. ( Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S, 2013) |
| " Present study is designed to investigate the immunomodulatory action of thalidomide in Klebsiella pneumoniae B5055 induced acute lung infection in BALB/c mice." | 7.76 | Thalidomide treatment modulates macrophage pro-inflammatory function and cytokine levels in Klebsiella pneumoniae B5055 induced pneumonia in BALB/c mice. ( Chhibber, S; Harjai, K; Kumar, V, 2010) |
| "Autoimmune events included pneumonitis (6 [13%]) and hypothyroidism (5 [10%]), mostly ≤ grade 2." | 6.84 | Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. ( Badros, A; Dell, C; Dogan, A; Goloubeva, O; Hyjek, E; Kocoglu, M; Lederer, E; Lesokhin, A; Ma, N; Milliron, T; Philip, S; Rapoport, AP; Singh, Z, 2017) |
| " Thalidomide is nowadays used for the treatment of several conditions including multiple myeloma (MM)." | 4.88 | Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature. ( Gonçalves, R; Lopes, J; Macedo, G; Sobrinho Simões, M; Vilas-Boas, F, 2012) |
| "Pomalidomide, previously used to treat multiple myeloma, has been reported to cause acute pulmonary toxicity that improves with drug discontinuation." | 3.88 | Pulmonary toxicity associated with pomalidomide. ( Blanc, PD; Brown, JK; Callahan, EC; Elicker, B; Gajic, S; Ley, B, 2018) |
| "The combination of lenalidomide, bortezomib and dexamethasone (RVD) has shown excellent efficacy in patients with relapsed or refractory multiple myeloma (RRMM)." | 3.79 | Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. ( Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S, 2013) |
| " Present study is designed to investigate the immunomodulatory action of thalidomide in Klebsiella pneumoniae B5055 induced acute lung infection in BALB/c mice." | 3.76 | Thalidomide treatment modulates macrophage pro-inflammatory function and cytokine levels in Klebsiella pneumoniae B5055 induced pneumonia in BALB/c mice. ( Chhibber, S; Harjai, K; Kumar, V, 2010) |
| "Autoimmune events included pneumonitis (6 [13%]) and hypothyroidism (5 [10%]), mostly ≤ grade 2." | 2.84 | Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. ( Badros, A; Dell, C; Dogan, A; Goloubeva, O; Hyjek, E; Kocoglu, M; Lederer, E; Lesokhin, A; Ma, N; Milliron, T; Philip, S; Rapoport, AP; Singh, Z, 2017) |
| "Treatment benefit in multiple myeloma (MM) patients with high-risk cytogenetics remains suboptimal." | 1.62 | Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. ( Alegre, A; Campana, F; Delimpasi, S; Facon, T; Harrison, SJ; Hulin, C; Inchauspé, M; Macé, S; Perrot, A; Richardson, P; Risse, ML; Simpson, D; Spencer, A; Sunami, K; van de Velde, H; Vlummens, P; Wang, MC; Yong, K, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 3 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Certan, M | 1 |
| Garcia Garrido, HM | 1 |
| Wong, G | 1 |
| Heijmans, J | 1 |
| Grobusch, MP | 1 |
| Goorhuis, A | 1 |
| Zhou, X | 1 |
| Steinhardt, MJ | 1 |
| Grathwohl, D | 1 |
| Meckel, K | 1 |
| Nickel, K | 1 |
| Leicht, HB | 1 |
| Krummenast, F | 1 |
| Einsele, H | 1 |
| Rasche, L | 1 |
| Kortüm, KM | 1 |
| Harrison, SJ | 1 |
| Perrot, A | 1 |
| Alegre, A | 1 |
| Simpson, D | 1 |
| Wang, MC | 1 |
| Spencer, A | 1 |
| Delimpasi, S | 1 |
| Hulin, C | 1 |
| Sunami, K | 1 |
| Facon, T | 1 |
| Vlummens, P | 1 |
| Yong, K | 1 |
| Campana, F | 1 |
| Inchauspé, M | 1 |
| Macé, S | 1 |
| Risse, ML | 1 |
| van de Velde, H | 1 |
| Richardson, P | 1 |
| Badros, A | 1 |
| Hyjek, E | 1 |
| Ma, N | 1 |
| Lesokhin, A | 1 |
| Dogan, A | 1 |
| Rapoport, AP | 1 |
| Kocoglu, M | 1 |
| Lederer, E | 1 |
| Philip, S | 1 |
| Milliron, T | 1 |
| Dell, C | 1 |
| Goloubeva, O | 1 |
| Singh, Z | 1 |
| Tian, C | 1 |
| Yang, H | 1 |
| Zhu, L | 1 |
| Zhang, Q | 1 |
| Cao, Z | 1 |
| Zhang, Y | 1 |
| Chen, Y | 1 |
| Shen, Y | 1 |
| Ma, HF | 1 |
| Cai, JF | 1 |
| Hua, YQ | 1 |
| Zou, J | 1 |
| Guan, JL | 1 |
| Gajic, S | 1 |
| Callahan, EC | 1 |
| Brown, JK | 1 |
| Elicker, B | 1 |
| Ley, B | 1 |
| Blanc, PD | 1 |
| Amraoui, K | 1 |
| Belhadj, K | 1 |
| Maître, B | 1 |
| Jannière-Nartey, C | 1 |
| Dupuis, J | 1 |
| Shah, JJ | 1 |
| Stadtmauer, EA | 1 |
| Abonour, R | 1 |
| Cohen, AD | 1 |
| Bensinger, WI | 1 |
| Gasparetto, C | 1 |
| Kaufman, JL | 1 |
| Lentzsch, S | 1 |
| Vogl, DT | 1 |
| Gomes, CL | 1 |
| Pascucci, N | 1 |
| Smith, DD | 1 |
| Orlowski, RZ | 1 |
| Durie, BG | 1 |
| Bhat, MA | 1 |
| Al-Omar, MA | 1 |
| Ansari, MA | 1 |
| Zoheir, KM | 1 |
| Imam, F | 1 |
| Attia, SM | 1 |
| Bakheet, SA | 1 |
| Nadeem, A | 1 |
| Korashy, HM | 1 |
| Voronkov, A | 1 |
| Berishvili, V | 1 |
| Ahmad, SF | 1 |
| Wyplosz, B | 1 |
| Lerolle, U | 1 |
| Israël-Biet, D | 1 |
| Dougados, J | 1 |
| Lillo-Le Louët, A | 1 |
| Ghez, D | 1 |
| Pouchot, J | 1 |
| Kumar, V | 1 |
| Harjai, K | 1 |
| Chhibber, S | 1 |
| Qin, Y | 1 |
| Shi, YK | 1 |
| He, XH | 1 |
| Yang, JL | 1 |
| Zhang, CG | 1 |
| Zhou, SY | 1 |
| Liu, XF | 1 |
| Liu, P | 1 |
| Yang, S | 1 |
| Zhou, LQ | 1 |
| Han, XH | 1 |
| Yao, JR | 1 |
| Zagouri, F | 1 |
| Roussou, M | 1 |
| Kastritis, E | 1 |
| Koureas, A | 1 |
| Tsokou, E | 1 |
| Migkou, M | 1 |
| Gavriatopoulou, M | 1 |
| Nikitas, N | 1 |
| Gkotzamanidou, M | 1 |
| Terpos, E | 1 |
| Dimopoulos, MA | 1 |
| Vilas-Boas, F | 1 |
| Gonçalves, R | 1 |
| Sobrinho Simões, M | 1 |
| Lopes, J | 1 |
| Macedo, G | 1 |
| Jimenez-Zepeda, VH | 1 |
| Reece, DE | 1 |
| Trudel, S | 1 |
| Chen, C | 1 |
| Tiedemann, R | 1 |
| Kukreti, V | 1 |
| Uthoff, K | 1 |
| Zehr, KJ | 1 |
| Gaudin, PB | 1 |
| Kumar, P | 1 |
| Cho, PW | 1 |
| Vogelsang, G | 1 |
| Hruban, RH | 1 |
| Baumgartner, WA | 1 |
| Stuart, RS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| 1454GCC: Phase I/II Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma[NCT02289222] | Phase 1/Phase 2 | 48 participants (Actual) | Interventional | 2014-12-30 | Terminated (stopped due to Due to the inclusion of an IMid in combination with pembrolizumab, Study Sponsor terminated the study.) | ||
| A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma[NCT01464034] | Phase 1/Phase 2 | 136 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Lack of enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Establish the safety and tolerability of Pomalidomide and Dexamethasone in combination with MK-3475 (NCT02289222)
Timeframe: 24 month
| Intervention | Participants (Count of Participants) |
|---|---|
| Pomalidomide, Dexamethasone & MK-3475 | 48 |
PFS will be measured in all participants. Survival and PFS functions were estimated using the Kaplan-Meier method. The Cox regression model was used to assess the following plausible risk factors for OS and PFS: age, isotype, number of cycles of therapy, and cytogenetic profile. (NCT02289222)
Timeframe: PFS assessments will take place after starting study therapy with MD-3475 and will continue until the start of a new anti-neoplastic therapy, disease progression, death, or the end of study up to an average of 24 months.
| Intervention | Months (Median) |
|---|---|
| Pomalidomide, Dexamethasone & MK-3475 | 17.4 |
The identification of a biomarker for response by evaluating PD-1/PDL-1 expression in patients' bone marrow aspirate samples will be analyzed in order to help select patients for future anti-PD-1 therapy. The main exploratory biomarker analysis was to examine potential correlation between expression of PD-1 on T cells and PD-L1 on myeloma cells with clinical outcome using the following parameters: response rate focusing on responses ≥ very good partial response (VGPR) and PFS. SAS software (v.9.4; SAS Institute, Inc, Cary, NC) was used for statistical analyses. (NCT02289222)
Timeframe: Tissue sample collection will take place before starting study therapy with MK-3475 at baseline and again at time of relapse as defined by the International Myeloma Working Group Response Criteria (Average of up to 24months)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Negative | Weak Positive | Positive | |
| Pomalidomide, Dexamethasone & MK-3475 | 10 | 6 | 13 |
1 review available for thalidomide and Pneumonia
| Article | Year |
|---|---|
Thalidomide-induced acute cholestatic hepatitis: case report and review of the literature.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemical and Drug Induc | 2012 |
2 trials available for thalidomide and Pneumonia
| Article | Year |
|---|---|
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2017 |
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Ma | 2015 |
14 other studies available for thalidomide and Pneumonia
| Article | Year |
|---|---|
Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Cohort Studies; Community-Acquired Infections; D | 2022 |
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2020 |
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplasti | 2021 |
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 2017 |
Infliximab associated with life-threatening lung infection in a patient with Behcet disease with intestinal and hematopoietic system involvement: A case report.
Topics: Antirheumatic Agents; Behcet Syndrome; Cyclosporine; Female; Glucocorticoids; Humans; Immunosuppress | 2017 |
Pulmonary toxicity associated with pomalidomide.
Topics: Antineoplastic Agents; Humans; Lung; Male; Middle Aged; Multiple Myeloma; Pneumonia; Pulmonary Fibro | 2018 |
Pulmonary toxicity after long-term treatment with lenalidomide in two myeloma patients.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Drug Administration Schedule; Fatal | 2013 |
Design and Synthesis of N-Arylphthalimides as Inhibitors of Glucocorticoid-Induced TNF Receptor-Related Protein, Proinflammatory Mediators, and Cytokines in Carrageenan-Induced Lung Inflammation.
Topics: Animals; Behavior, Animal; Carrageenan; Cytokines; Drug Design; Enzyme Inhibitors; Female; Inflammat | 2015 |
Thalidomide-induced pneumonitis.
Topics: Aged; Angiogenesis Inhibitors; Humans; Male; Multiple Myeloma; Pneumonia; Thalidomide; Tomography, X | 2008 |
Thalidomide treatment modulates macrophage pro-inflammatory function and cytokine levels in Klebsiella pneumoniae B5055 induced pneumonia in BALB/c mice.
Topics: Animals; Cells, Cultured; Cytokines; Inflammation Mediators; Klebsiella Infections; Klebsiella pneum | 2010 |
[Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxo | 2010 |
Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias.
Topics: Aged; Animals; Female; Humans; Immunologic Factors; Lenalidomide; Male; Mice; Middle Aged; Paraprote | 2011 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexa | 2013 |
Thalidomide as replacement for steroids in immunosuppression after lung transplantation.
Topics: Animals; Azathioprine; Cyclosporine; Dogs; Graft Rejection; Immunosuppressive Agents; Lung; Lung Tra | 1995 |